Assure Holdings Corp. Announces Expansion Into Vascular Surgery Market

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./

Assure Begins Work With Prominent Vascular Group

PARKER, CO, Sept. 19, 2017  /CNW/ - Assure Holdings Corp. (the "Company" or "Assure") (TSXV: IOM; OTCBB: ARHH), announces today that it has recently begun working with and performing intraoperative neuromonitoring (IONM) for a premier group of vascular surgeons in the Denver area. Vascular surgeons specialize in surgical treatment of the arteries that are critical circulatory pathways throughout the body. Assure's technologists are able to use their same equipment and skill set in vascular surgeries, just as they do in spine surgery, to monitor nerves and brain function in real time. 

Preston Parsons, Founder and CEO of Assure commented, "This marks a very significant step in the evolution of the company. Vascular surgery is a vastly underserved part of the IONM market. We are pleased to have technologists with the level of knowledge and skill needed to participate in these complicated surgeries."

Vascular surgery comprises about 1/3 of the IONM market in the United States. The most common vascular surgeries include carotid surgery and aortic surgery. IONM is also being adopted in other vascular procedures as the technology is more universally recognized as improving patient outcomes. 

Numerous vascular procedures place one or more aspects of the patient's nervous system at risk, either from direct surgical manipulation or ischemia secondary to the vascular procedure being preformed.  IONM can help assess these neural structures during the vascular procedure to help ensure the safety and functionality of the nervous structures.  For example, during a Carotid Endarterectomy blood flow through the operative carotid artery is occluded, decreasing the overall blood flow to the brain. IONM is utilized during this procedure to help ensure that adequate perfusion of the cerebral cortex is maintained. Overall, IONM provides invaluable information to vascular surgeons regarding functionality of nervous structures placed at risk from the vascular operation.

Parsons continued, "Furthermore, now that we have expanded into vascular surgery, our current addressable market has increased significantly and has helped pave the way for future expansion into this underserved surgical vertical."

About Assure Holdings Corp.

Assure Holdings Corp. is a Colorado based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.  Assure: (i) employs its own staff of technologists and uses its own state of the art monitoring equipment, (ii) handles 100% of intraoperative neuromonitoring scheduling and setup, and (iii) bills for all technical services provided.  While Assure focuses primarily on supporting spinal surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities of the Corporation have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Assure anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, comments with respect to strategies, expectations, planned operations and future actions of the Company. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Assure to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Assure, including information obtained from third-party industry analysts and other third party sources, and are based on management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.

SOURCE Assure Holdings Corp.

View original content: http://www.newswire.ca/en/releases/archive/September2017/19/c8953.html